Updating results

2439 results

Sort: Relevance | Date

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015

Erectile dysfunction: Alprostadil cream (ESNM50)

Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published December 2014

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Premature ejaculation: dapoxetine (ESNM40)

Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

Evidence summary Published May 2014

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

Summary of the evidence on tiotropium/olodaterol (Spiolto Respimat) for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published May 2016

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

Advice on the use of Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds to aid local decision-making

Medtech innovation briefing Published November 2014

First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

KTT8 First-choice antidepressant use in adults with depression or generalised anxiety disorder Options for local implementation

Key therapeutic topic Published January 2015 Last updated February 2016

The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)

Advice on the use of the Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy to aid local decision-making

Medtech innovation briefing Published February 2015

Mollii suit for spasticity (MIB100)

Advice on the use of Mollii suit (formerly Elektrodress; a therapeutic electrical stimulation jacket and trousers) for spasticity to aid local decision-making

Medtech innovation briefing Published March 2017

End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia (MIB10)

Advice on the use of End-tidal Control software with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia..

Medtech innovation briefing Published September 2014

LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)

Advice on the use of the LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands to aid local decision-making

Medtech innovation briefing Published April 2015

VAAFT for treating anal fistulae (MIB102)

Advice on the use of VAAFT for treating anal fistulae to aid local decision-making

Medtech innovation briefing Published April 2017

Zio Service for detecting cardiac arrhythmias (MIB101)

Advice on the use of the Zio Service (a remote cardiac monitoring system) for detecting cardiac arrhythmias to aid local decision-making

Medtech innovation briefing Published March 2017

Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

Summary of the evidence on docetaxel for treating hormone-sensitive metastatic prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2016

Infantile haemangioma: topical timolol (ESUOM47)

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

Cystic fibrosis: long-term azithromycin (ESUOM37)

Summary of the evidence on long-term azithromycinoral for treating cystic fibrosis (CF) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Laxatives (KTT1)

KTT1 Laxatives Options for local implementation Review and, if appropriate, revise prescribing

Key therapeutic topic Published January 2015

Chronic urticaria: off-label doses of cetirizine (ESUOM31)

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Scleroderma: oral mycophenolate (ESUOM32)

Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Hemosep for cell salvage (MIB103)

MIB103 Hemosep for cell salvage Summary The technology described in this briefing

Medtech innovation briefing Published May 2017

The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

Advice on the use of the NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (CKD)..

Medtech innovation briefing Published November 2014

The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

Advice on the use of the Juxta CURES adjustable compression system for treating venous leg ulcers to aid local decision-making

Medtech innovation briefing Published March 2015

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

Evidence summary Published January 2013

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015

C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

Evidence summary Published December 2015

Minocycline (KTT11)

KTT11 Minocycline Options for local implementation Review and, if appropriate, revise

Key therapeutic topic Published January 2015

Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

Advice on the use of the Active B12 assay for diagnosing vitamin B12 deficiency to aid local decision-making

Medtech innovation briefing Published September 2015

AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)

Advice on the use of the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis to aid local decision-making

Medtech innovation briefing Published December 2015

Secca System for faecal incontinence (MIB66)

Advice on the use of the Secca system for treating faecal incontinence to aid local decision-making

Medtech innovation briefing Published May 2016

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014